The Court of Appeal overturned the Patents Court decision to strike out Glaxo Group’s (GSK’s) claim for an Arrow declaration in proceedings concerning a number of patents relating to dry powder inhaler formulations used in the treatment of respiratory diseases. The Court of Appeal held that GSK’s claim for an Arrow declaration was sufficiently realistic to be allowed to proceed to trial.
Case date: 28 June 2018
Case number: [2018] EWCA Civ 1496
Court: Court of Appeal of England and Wales, Civil Division
A full summary of this case has been published on Kluwer IP Law.
________________________
To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.
